COVID-19 Rapid Response: Assessment of the Effect of lung-directed Site-Specific Immunomodulator (SSI) in clinical trial QBKPN-CV-01: Assessment of the Effect of QBKPN Site-Specific Immunomodulator (SSI) on Innate Immunity and COVID-19 Vaccine Immune Response and Maintenance in Adults 65 Years of Age or Older

Major Funding
$5,426,172.00

Grant Value

2023-24

Fiscal Year

Description

###############################################################################################################################################################################################################################################################

Expected Results

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Grant Details
Recipient

Qu Biologics Inc.

Location

Burnaby, BC V5G 4X4

Agreement Details

Number: 995430

Reference: 172-2022-2023-Q2-995430

Timeline

Start: Sept. 1, 2022

End: March 31, 2024

Program

Industrial Research Assistance Program Contributions to Firms

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …

Sector

Professional, scientific and technical services (541710)

Your Contribution

Calculate how much you personally contributed to this grant through your taxes.

Calculate My Share
Share This Grant
Back to All Grants